Why are the financial statements for Otezla® described as 'special-purpose' and 'abbreviated'?

Celgene advised Amgen that Otezla® was a fully integrated part of its operations and not a stand-alone entity. Therefore, Celgene had not maintained separate accounts or prepared distinct financial statements for the product line historically, making it impracticable to provide full, traditional financial statements in compliance with all SEC rules.

What financial information is being provided for the Otezla® product line?

Amgen is filing audited special-purpose financial statements for the Otezla® product line as of and for the year ended December 31, 2018. Additionally, unaudited interim special-purpose financial statements as of September 30, 2019, and for the nine months ended September 30, 2019, are provided, along with audited comparative figures for December 31, 2018, and the nine months ended September 30, 2018.

What is the purpose of the pro forma financial information?

The unaudited pro forma condensed combined financial information is presented to show how the combined entity (Amgen including Otezla®) might have looked financially if the acquisition had occurred earlier. It provides investors with a perspective on the potential combined financial impact of the Otezla® acquisition on Amgen's income statement and balance sheet.

AMGN 8-K SEC Disclosure

Q: Why is Amgen filing an amendment to an 8-K?

Amgen is filing this amendment (8-K/A) to provide the necessary financial statements and pro forma information related to its acquisition of the Otezla® product line from Celgene, as required by SEC regulations for significant business acquisitions.

Summary

Amgen Inc. filed an 8-K/A amendment on January 26, 2020, primarily to provide updated financial information related to its acquisition of the Otezla® product line from Celgene. Amgen determined that Otezla® qualifies as a "business" and its acquisition necessitates the filing of specific financial statements under SEC regulations. Due to the integrated nature of Otezla® within Celgene's operations, detailed standalone historical financial statements were not available. Consequently, Amgen is providing abbreviated special-purpose financial statements for the Otezla® product line as of December 31, 2018, and for the year then ended, along with interim statements for the nine months ended September 30, 2019. This filing also includes pro forma financial information reflecting the combined entity post-acquisition. This amendment is crucial for investors to understand the financial performance and position of the Otezla® asset that Amgen has acquired. While full historical financials are unavailable due to Celgene's accounting practices, the provided special-purpose and pro forma statements offer insight into the product line's contribution and its expected impact on Amgen's consolidated financials. Investors should review these exhibits to assess the financial significance of the Otezla® acquisition and its potential contribution to Amgen's future revenue and profitability.

Key Highlights

1Amgen filed an 8-K/A amendment to provide financial statements and pro forma information for the acquired Otezla® product line.
2The Otezla® product line was determined to meet the definition of a "business" under SEC rules.
3Audited financial statements for Otezla® as of and for the year ended December 31, 2018, are being filed.
4Unaudited interim financial statements for Otezla® as of and for the nine months ended September 30, 2019, are also being filed.
5Celgene stated that preparing full, standalone financial statements for Otezla® was impracticable due to its integrated nature and lack of separate accounting.
6Amgen is filing abbreviated, special-purpose financial statements for the acquired product line.
7Unaudited pro forma condensed combined financial information is provided to reflect the acquisition's impact on Amgen.

AMGEN INC 8-K/A Report, Exhibit Filing (Jan 27, 2020)

Summary

Key Highlights

Frequently Asked Questions